Pharmaceutical care for a case of severe myelosuppression induced by meropenem injection combined with vancomycin injection

doi:10.19803/j.1672-8629.20220160

Abstract

Abstract: Objective To remind clinicians of possible adverse reactions of granulocytic myelosuppression induced by meropenem and vancomycin injections in clinical use. Methods One case of severe granulocytic myelosuppression was reported in a patient after cerebral hemorrhage surgery. Correlation analysis of the adverse reactions was conducted to identify the possible drug responsible for the occurrence of granulocytic myelosuppression in the patient. Results The severity of the adverse reactions was grade IV myelosuppression. The patient's condition and concomitant medication were excluded before the cause of severe myelosuppression was determined to be the combined use of antibacterial meropenem and vancomycin injections. The relevance of adverse reactions was evaluated as “probable”. The drug was immediately discontinued and the patient was improved after symptomatic treatment. Conclusion Adverse reactions of grade IV myelosuppression induced by the combined use of antibacterial meropenem and vancomycin injections are rarely reported and should be identified during clinical drug treatment.

Key words: meropenem, granulocytopenia, severe myelosuppression, vancomycin, polymyxin-B

CLC Number:

R978.1

LIU Baohua, SHEN Aizong, SU Dan. Pharmaceutical care for a case of severe myelosuppression induced by meropenem injection combined with vancomycin injection[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 339-342.

References

[1] CHEATHAM SC, KAYS MB, SMITH DW, et al.Steady-state pharmacokinetics and pharmaco- dynamics of meropenem in hospitalized patients[J]. Pharmacotherapy, 2008, 28(6): 691-698.
[2] LI YY, ZHU YB.A case of platelet elevation induced by meropenem for injection[J]. Chinese Journal of Phamiacovigilance(中国药物警戒), 2017.14(8): 505-506.
[3] Neurocritical Expert Committee of Neurosurgery Surgeons Branch of Chinese Medical Doctor Association, Neurosurgery Critical Care Group of Neurosurgery Branch of Beijing Medical Association, WANG N, et al. Chinese Expert Consensus Edition on Diagnosis and Treatment of CNS Infection in Neurosurgery (2021th edition)[J]. Chinese Journal of Neurosurgery(中华神经外科杂志), 2021, 37(1): 2-15.
[4] ANDRÈS, VILLALBA, ZULFIQAR, et al. State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies[J]. Journal of Clinical Medicine, 2019, 8(9): 1351.
[5] JUSTO JA, BOSSO JA.Adverse reactions associated with systemic polymyxin therapy[J]. Pharmacotherapy, 2015, 35(1): 28-33.
[6] CORRIGAN JJ JR, KIERNAT JF.Effect of polymyxin B sulfate on endotoxin activity in a gram-negative septicemia model[J]. Pediatr Res, 1979, 13: 48-51.
[7] PAN SJ.Analysis of the efficacy of Intravenous plus intrathecal/ intraventricular ventricle injection of polymyxin for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii[D]. Hangzhou: Zhejiang University, 2018.
[8] SUN B, BAI YN, ZHANG YY, et al.Literature analysis of 190 adverse vancomycin reactions[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2021, 18(2): 106-109.
[9] HE N, SU S,YE Z, et al.Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological Society[J]. Clin Infect Dis, 2020, 71(Suppl 4): S363-S371.
[10] HUANG XJ, GAO NJ, HUANG L, et al.Neutropenia induced by meropenem in a newborn[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2017, 19(3): 226-227.
[11] QI YQ.Analysis of leukopenia caused by meropenem[J]. Women’s Health Research(中外女性健康研究), 2017(8): 96-99.
[12] GABRIELE RIGHI, GIULIO DEL POPOLO.COVID-19 tsunami: the first case of a spinal cord injury patient in Italy[J]. Spinal Cord Series and Cases, 2020, 6(22): 1-5.
[13] LIU YR, HE YJ.Thrombocytosis caused by meropenem for injection[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2021, 3(10): 544-545.
[14] HUSSAIN K, SALAT MS, MOHAMMAD N, et al.Meropenem-induced pancytopenia in a preterm neonate: a case report[J]. Med Case Rep, 2021, 15(1): 25-25.
[15] NEFTEL KA, HAUSER SP, MULLER MR.Inhibition of granulopoiesis in vivo and in vitro by beta -lactam antibiotics[J]. J Infect Dis, 1985, 152(1): 90-98.
[16] DAVID NG, HENRY FC, MICHAEL SS, et al.The Sanford Guide To Antimicrobial Therapy 2020 (50th edition)[M]. New York: Antimicrobial Therapy, Inc, 2020.
[17] National Health Commission of the People’s Republic of China. Administrative Measures on Reporting and Monitoring of ADR[EB/OL].(2011-05-04)[2022-04-01].https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504162501325.html.
[18] ANDRFES E, MALOISEL F.Idiosyncratic drug-induced agranulocytosis or acute neutropenia[J]. Curr Opin Hematol, 2008, 15(1): 15-21.
[19] BHATT V, SALEEM A.Review: drug-induced neutropenia-- pathophysiology,clinical features and management[J]. Ann Clin U b Sci, 2004, 34(2): 131-137.
[20] The society of chemotherapy, Chinese Anti-Cancer Association, Committee of neoplastic supportive-care (CONS), et al. Consensus on the clinical diagnosis, treatment, and prevention of chemotherapy- induced neutropenia in China (2019th edition)[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2019, 46(17): 876-882.
[21] Chinese Society of Hematology, Chinese Medical Association, Chinese Medical Doctor Association, et al. Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020th edition)[J]. Chinese Journal of Hematology(中华血液学杂志), 2020, 41(12): 969-978.
[22] ANDERSOHN F, KONZEN C, GARBE E.Systematic review: agranulocytosis induced by nonchemotherapy drugs[J]. Ann Intern Med, 2007 (146): 657-665.